Quick Answer
Crinetics Pharmaceuticals, Inc. reported Net Income Loss of -$465.32 million for the year ending 2025.
- Crinetics Pharmaceuticals, Inc. showed a decrease of -55.9% in Net Income Loss from 2024 to 2025.
- This data is from Crinetics Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: -$2.61 million | Q2 2017: -$1.65 million | Q3 2017: -$2.38 million | Q4 2017: -$2.52 million | Q1 2018: -$5.46 million | Q2 2018: -$5.57 million | Q3 2018: -$7.59 million | Q4 2018: -$8.50 million | Q1 2019: -$9.02 million | Q2 2019: -$12.43 million | Q3 2019: -$14.43 million | Q4 2019: -$14.55 million | Q1 2020: -$17.36 million | Q2 2020: -$16.49 million | Q3 2020: -$18.32 million | Q1 2021: -$22.90 million | Q2 2021: -$26.10 million | Q3 2021: -$27.85 million | Q1 2022: -$34.63 million | Q2 2022: -$42.38 million | Q3 2022: -$41.93 million | Q1 2023: -$46.00 million | Q2 2023: -$50.98 million | Q3 2023: -$57.46 million | Q1 2024: -$66.93 million | Q2 2024: -$74.06 million | Q3 2024: -$76.83 million | Q1 2025: -$96.77 million | Q2 2025: -$115.64 million | Q3 2025: -$130.09 million.
- Over the full 10 years of available data (2016 to 2025), Crinetics Pharmaceuticals, Inc.'s Net Income Loss has declined by 7,630.8%.
- Historical annual values: Fiscal year 2025: -$465.32 million | Fiscal year 2024: -$298.41 million | Fiscal year 2023: -$214.53 million | Fiscal year 2022: -$163.92 million | Fiscal year 2021: -$107.64 million | Fiscal year 2020: -$73.81 million | Fiscal year 2019: -$50.42 million | Fiscal year 2018: -$27.12 million | Fiscal year 2017: -$9.16 million | Fiscal year 2016: -$6.02 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: